Navigation Links
A New Era in Cell Biology: German Company Develops Groundbreaking Alternative to Stem Cell Therapy

KIEL, Germany, March 5 /PRNewswire/ -- In mid-March the German Bundestag (Lower House) is due to vote on an amendment to the German Stem Cell Act. The opposing poles in the debate on embryonic stem cell research could not be further apart: its proponents are calling for the complete liberalisation of stem cell research, while its critics are in favour of a general ban on the use of human stem cells, which are produced from embryos. While the Bundestag debates on a new regulation, Blasticon Biotechnologische Forschung GmbH has made a breakthrough in cell biology:

Blasticon has at its disposal a patented technology based on which monocytes (mature white blood cells) from blood extracted from veins can be turned into cells with programmable properties comparable to those of stem cells and differentiated into different functional cells for diverse applications in diagnostics and therapy.

Cellular quick-change artists in the fight against widespread diseases

"We work with mononuclear cells, which can simply be extracted from blood," says Prof. Dr. med. Fred Fandrich, Director of the Clinic for General Surgery and Thoracic Surgery at the University Clinic of Schleswig-Holstein, Kiel, and founder of the company. "In the second step of our patented procedure we can 'reprogram' these programmable cells into the desired target cells, for example liver or muscle cells or cells in pancreatic islets of Langerhans." The therapeutic possibilities lie in replacing defective or missing cells (regenerative medicine) or producing cells that regulate the immune system. A significant advancement in the treatment of autoimmune diseases or for transplant medicine.

The "reprogrammed" cells can be used both as diagnostic agents or for therapeutic purposes. Inflammatory bowel diseases (Morbus Crohn, Colitis ulcerosa), diabetes, rheumatism, cardiac infarction, liver diseases and kidney and liver transplants, among others, are among the main therapeutic areas. Blasticon's therapeutic agents are for the most part in advanced stages of preclinical or clinical phases of development. In most cases, the medical fields of application described necessitate costly lifelong treatment. Blasticon's reprogrammed cells make it possible to attack illnesses at their origin and to prevent long duration of treatment. A further possible positive effect of the technologies is significant cost-reduction in the health system.

Products which are ready for application and soon to be introduced onto the market

The diagnostic application of the in vitro acute toxicity test "NeoHeps" can be introduced onto the market as soon as NeoHelps has been successfully validated by the European Union (EU). The REACH programme, a new EU chemical regulation that came into force on 1 June 2007 is of particular importance here; it will in future oblige all manufacturers, importers and users of chemicals to evaluate their substances as being safe. This presents a great challenge to many industries, whether they produce shampoos, kitchen utensils, computers, televisions, furniture or clothing - owing to the implementation of REACH, over 30,000 known chemicals are to be retested for their toxic safety. New chemical entities must also be tested with the REACH test regime. According to estimates, around 3,500 tests a year will be necessary.

Up to now, Blasticon's "NeoHeps" test system has passed all necessary tests within the EU test framework and has therefore been able to secure itself a clear market lead. In addition, "NeoHeps" could be of considerable benefit to the pharmaceutical industry, for example in examining the effectiveness and undesirable side effects of medicines. The advantages are less animal testing, unlimited availability of the required cells and cost-reduction in the area of drug development.

Prof. Dr. med Fandrich comments on the current political debate: "Personally, I do not think much of the use of embryonic cells for clinical application. Pure research and clinical research should be kept separate from one another. Embryonic stem cells are necessary so that we can gain a better understanding of the programmability of cells."

About Blasticon Biotechnologische Forschung GmbH

Blasticon is a biotechnology company that is active in the fields of cellular medicine and in vitro diagnostics. Blasticon has at its disposal a patented technology that enables it to turn monocytes (mature white blood cells) from extracted blood into PCMO (programmable cells of monocytic origin = stem-cell-like human cells) and to differentiate them into different functional cells for diverse applications in diagnostics and therapy. The company was founded in 2002.


PRint Agentur fur Offentlichkeitsarbeit GmbH

Katja Schmidt

Ottobrunner Strasse 26

82008 Unterhaching


Telephone: +49-89-66532-1280

Telefax: +49-89-66532-1115


SOURCE Blasticon Biotechnologische Forschung GmbH
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Germany Hosts World Leading Medical Industry Fair
2. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
3. Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany
4. ROBODOC(R) Emerges as a Curexo Technology Company at Upcoming Orthopaedic Surgeons Conference in San Francisco
5. Stem Cell Company t2cure Appoints Dr Rueck Head of Clinical Operations
6. National Stem Cell Holding, Inc. Has Engaged BMA Securities to Assist and Advise the Company With Its Current Capital Raise of $3,500,000
7. European Company NovaSecta Joins First Chinese CRO Service Alliance for Drug Discovery Solutions
8. Nastech Pharmaceutical Company Implements Additional Workforce Reduction as Part of Previously Announced Corporate Restructuring
9. Halogen Announces Record Year - Company Solidifies Leadership Position, Secures Strategic Wins Over Competition
10. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
11. Alynx, Co. Completes Merger With Medical Device Company MiMedx, Inc.
Post Your Comments:
(Date:6/27/2016)... 27, 2016  Global demand for enzymes is ... 2020 to $7.2 billion.  This market includes enzymes ... products, biofuel production, animal feed, and other markets) ... biocatalysts). Food and beverages will remain the largest ... consumption of products containing enzymes in developing regions.  ...
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading software ... Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and ... clinical trial team. , Using the CONSULT module, patients and physicians can schedule a ...
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks ... to industrial engineering, was today awarded as one ... selection of the world,s most innovative companies. Ginkgo ... scale for the real world in the nutrition, ... engineers work directly with customers including Fortune 500 ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
Breaking Biology Technology:
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
(Date:6/15/2016)... York , June 15, 2016 ... new market report titled "Gesture Recognition Market by Application ... Forecast, 2016 - 2024". According to the report, the  ... 11.60 billion in 2015 and is estimated to ... USD 48.56 billion by 2024.  Increasing ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... ...
Breaking Biology News(10 mins):